- Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trialChen, H.; Hu, Y.; Fan, Y.; Wu, G.; Cang, S.; Yang, Y.; Yang, N.; Ma, R.; Jing, G.; Liu, A.; Xu, X.; Tang, S.; Cheng, Y.; Yu, Y.; Wu, Y-L.
- A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)Zhang, L.; Fang, W.; Yu, Q.; Zhang, H.; Wu, G.; Wu, D.; Lin, Y.; Zhu, J.; Chen, J.; Hu, X.; Lan, B.; Zhou, Z.; Lin, H.; Wang, Z.; Lei, X.; Pan, S.; Chen, L.; Zhang, J.; Kong, T.; Yu, H.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinibTan, Daniel Shao-Weng; Kim, Tae Min; Guarneri, Valentina; Voon, Pei Jye; Lim, Boon Khaw; Wislez, Marie; Huang, Cheng; Liam, Chong Kin; Mazieres, Julien; Tho, Lye Mun; Hayashi, Hidetoshi; Nhung, Nguyen; Chia, Puey Ling; De Marinis, Filippo; Le, Xiuning; Karachaliou, Niki; Brutlach, Sabine; Adrian, Svenja; Ellers-Lenz, Barbara; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced nonsmall cell lung cancer (NSCLC) harboring EGFR mutation
2阅读
